EMEA-002817-PIP05-23 - paediatric investigation plan
Faricimab
PIPHuman
Key facts
- Invented name
- Vabysmo
- Active Substance
- Faricimab
- Therapeutic area
- Eye disorders
- Decision number
- P/0006/2024
- PIP number
- EMEA-002817-PIP05-23
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of choroidal neovascularisation secondary to pathologic myopia
- Route(s) of administration
- Intravitreal use
- Contact for public enquiries
Roche Registration GmbH
E-mail: global.eu_regulatory_office@roche.com
Tel: +41 616879411- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date